Condition
Myelokathexis
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed2
Enrolling By Invitation1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07775313Phase 1Enrolling By Invitation
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
NCT00967785Phase 1Completed
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
NCT02231879Phase 2CompletedPrimary
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Showing all 3 trials